LPL Financial
PTGX icon

LPL Financial’s Protagonist Therapeutics PTGX Stock Holding History

LPL Financial’s Portfolio PTGX Stock Details PTGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		$1.14M Buy
8,110
+4,164
+106% +$593K ﹤0.01% 4387
2026
Q2 		$484K Buy
3,946
+1,153
+41% +$120K ﹤0.01% 5055
2026
Q1 		$294K Sell
2,793
-472
-14% -$41.8K ﹤0.01% 5197
2025
Q4 		$285K Sell
3,265
-1,729
-35% -$142K ﹤0.01% 5183
2025
Q3 		$332K Buy
4,994
+176
+4% +$10K ﹤0.01% 4978
2025
Q2 		$266K Sell
4,818
-70
-1% -$3.36K ﹤0.01% 4859
2025
Q1 		$236K Buy
+4,888
New +$205K ﹤0.01% 4741

Other funds holding PTGX

BlackRock
BlackRock New York $6.79T AUM 37.06% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $765B AUM 28.39% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.21T AUM
State Street
State Street Boston, Massachusetts $3.44T AUM 36.12% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.76T AUM
Invesco
Invesco Atlanta, Georgia $1.27T AUM 50.62% 1-Year Est. Return
Johnson & Johnson
Johnson & Johnson New Brunswick, New Jersey $762M AUM 69.66% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.92T AUM 36.1% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 20.64% 1-Year Est. Return

LPL Financial's PTGX Position: Q3 2026 in Review

LPL Financial increased its Protagonist Therapeutics (PTGX) stake by 106% in Q3 2026, buying an estimated $593K and bringing the position to 8,110 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #4387.

LPL Financial first reported a position in PTGX in Q1 2025 and has held it in 7 quarters since. 294 funds tracked by Wall St. Rank hold PTGX as of Q3 2026.

  • LPL Financial held 8,110 shares of Protagonist Therapeutics worth $1.14M as of Q3 2026.
  • LPL Financial bought 4,164 Protagonist Therapeutics shares in Q3 2026, an estimated $593K.
  • Protagonist Therapeutics made up ﹤0.01% of LPL Financial's portfolio in Q3 2026, its #4387 holding.
  • LPL Financial first reported a position in Protagonist Therapeutics in Q1 2025 and has held it in 7 quarters since.
  • 294 funds tracked by Wall St. Rank held Protagonist Therapeutics as of Q3 2026.

Based on LPL Financial's 13F filing for Q3 2026, filed 6 Nov 2026.